The objective of this study is to estimate the effectiveness of COVID-19 vaccines in people treated within the social security system whose vaccination status was reported to the epidemiological ...surveillance system.
Case-control study.
This was a case-control study conducted. The records of individuals with suspected cases of COVID-19 registered in the epidemiological surveillance system between February 1 and June 30, 2021, were studied. RT-qPCR was performed to determine SARS-CoV-2 infection; those with a positive result were considered cases, and those with a negative result were considered controls. The ratio between cases and controls was 1:1.3. The crude and adjusted vaccine effectiveness was considered the prevention of symptomatic infection and death and calculated as the difference between the dose and the risk, with a survival analysis among vaccinated people.
A total of 94,416 individuals were included, of whom 40,192 were considered cases and 54,224 controls; 3,781 (4.00%) had been vaccinated against COVID-19. Vaccination also proved to be a protective factor against COVID-19, especially in the population who received a second dose (OR = 0.31; 95% CI 0.28-0.35). With the application of the vaccine, there was a protective effect against mortality (OR = 0.76; 95% CI 0.66-0.87). Disease prevention was higher for the BNT162-2 mRNA vaccine (82%) followed by the ChAdOx1 vaccine (33%). In the survival analysis, vaccination provided a protective effect.
There was a positive impact of vaccines for the prevention of symptomatic COVID-19, with a second dose generating greater efficacy and a reduction in deaths.
There is no evidence of peptides-probiotics symbiosis as supplements in aquafeeds.BackgroundThere is no evidence of peptides-probiotics symbiosis as supplements in aquafeeds.To evaluate the effect of ...peptides and probiotics supplementation via diet on blood parameters and growth performance of juvenile Piaractus brachypomus, an Amazonian fish, during the growth-out phase.AimTo evaluate the effect of peptides and probiotics supplementation via diet on blood parameters and growth performance of juvenile Piaractus brachypomus, an Amazonian fish, during the growth-out phase.120 juvenile P. brachypomus (242.77 g) were placed into twelve 200-l tanks (10 fish/tank), housed in an indoor open system with constant water renovation (flow rate:1.50 l/minute). The experiment used a completely randomized design with a 4 × 5 factorial arrangement 4 doses of supplementation (CD: commercial diet; PepD: CD+1.50% of peptides per CD weight; ProD: CD+40.00 ml of activated probiotics per kg of diet (Lactobacillus spp., Rhodopseudomonas spp., Saccharomycetes spp.); PepProD: CD+Pep+Pro); 5 sampling times (zero, second, fourth, sixth, and eighth week); n = 3. Fish were fed twice a day at a feeding rate of 1% of body weight. At each sampling time, blood was collected and fish were measured for growth performance analysis. Data were analyzed by using two-way ANOVA and Tukey's test (p < 0.05).Methods120 juvenile P. brachypomus (242.77 g) were placed into twelve 200-l tanks (10 fish/tank), housed in an indoor open system with constant water renovation (flow rate:1.50 l/minute). The experiment used a completely randomized design with a 4 × 5 factorial arrangement 4 doses of supplementation (CD: commercial diet; PepD: CD+1.50% of peptides per CD weight; ProD: CD+40.00 ml of activated probiotics per kg of diet (Lactobacillus spp., Rhodopseudomonas spp., Saccharomycetes spp.); PepProD: CD+Pep+Pro); 5 sampling times (zero, second, fourth, sixth, and eighth week); n = 3. Fish were fed twice a day at a feeding rate of 1% of body weight. At each sampling time, blood was collected and fish were measured for growth performance analysis. Data were analyzed by using two-way ANOVA and Tukey's test (p < 0.05).The values of hematocrit (18.31%), leukocytes (1,216.67 mm3), neutrophils (81.27%), lymphocytes (18.73%), albumin (1.08 g/dl), relative growth rate (1.002%/day), and the Fulton allometric condition factor (2.03) remained constant throughout the experiment (p > 0.05). Plasma glucose decreased for all fish in the second week (59.56 mg/dl); then, that level increased in fish fed with the CD (89.00 mg/dl), while fish fed with PepD, ProD, and PepProD showed constant values (57.22 mg/dl). The plasma protein levels were constant in fish fed with the PepD and PepProD, (p > 0.05), while fish fed with the CD and ProD showed non-constant and higher values. At the end of the trial, fish fed with the PepProD showed the highest weight gain and the lowest feed conversion rate (39.66 g; 0.97).ResultsThe values of hematocrit (18.31%), leukocytes (1,216.67 mm3), neutrophils (81.27%), lymphocytes (18.73%), albumin (1.08 g/dl), relative growth rate (1.002%/day), and the Fulton allometric condition factor (2.03) remained constant throughout the experiment (p > 0.05). Plasma glucose decreased for all fish in the second week (59.56 mg/dl); then, that level increased in fish fed with the CD (89.00 mg/dl), while fish fed with PepD, ProD, and PepProD showed constant values (57.22 mg/dl). The plasma protein levels were constant in fish fed with the PepD and PepProD, (p > 0.05), while fish fed with the CD and ProD showed non-constant and higher values. At the end of the trial, fish fed with the PepProD showed the highest weight gain and the lowest feed conversion rate (39.66 g; 0.97).It is possible to maintain the stability of plasma glucose and plasma protein by supplementing diets with peptides, but the peptides-probiotics symbiosis administrated via diet contributes to maintaining the stability of plasma glucose and plasma protein and to improve the growth performance of juvenile P. brachypomus during the growth-out phase.ConclusionIt is possible to maintain the stability of plasma glucose and plasma protein by supplementing diets with peptides, but the peptides-probiotics symbiosis administrated via diet contributes to maintaining the stability of plasma glucose and plasma protein and to improve the growth performance of juvenile P. brachypomus during the growth-out phase.
As individuals age, they become increasingly prone to infectious diseases, many of which are vaccine-preventable diseases (VPDs). Adult immunization has become a public health priority in the modern ...era, yet VPDs vaccination rates for adults are low worldwide. In Central America and Caribbean, national recommendations and vaccination practices in adults differ across countries, and adult vaccination coverage data are limited. An advisory board comprised infectious disease experts, pulmonologists, geriatricians, occupational health, and public health professionals for Central America and Dominican Republic was convened to: a) describe adult immunization practices in these countries; b) discuss challenges and barriers to adult vaccination; and c) find strategies to increase awareness about VPDs. The advisory board discussions reflect that national immunization guidelines typically do not include routine vaccine recommendations for all adults, but rather focus on those with risk factors. This is the case for influenza, pneumococcal, and hepatitis B immunizations. Overall, knowledge lacks about the VPD burden among health-care professionals and the general public. Even more, there is insufficient information on vaccinology for students in medical schools. Actions from the responsible authorities - medical schools and scientific societies which can advocate for vaccination and a better knowledge in vaccinology - can help address these issues. A preventive medicine culture in the workplace may contribute to the advancement of public opinion on vaccination. Promoting vaccine education and research could be facilitated via working groups formed by disease experts, public and private sectors, and supranational authorities, in an ethical and transparent manner.
Protein phosphorylation and dephosphorylation are increasingly recognized as important processes for regulating multiple physiological mechanisms. Phosphorylation is carried out by protein kinases ...and dephosphorylation by protein phosphatases. Phosphoprotein phosphatases (PPPs), one of three families of protein serine/threonine phosphatases, have great structural diversity and are involved in regulating many cell functions. PP2C, a type of PPP, is found in
, a dimorphic protozoan parasite and the causal agent of leishmaniasis. The aim of this study was to clone, purify, biochemically characterize and quantify the expression of PP2C in
(
PP2C). Recombinant
PP2C dephosphorylated a specific threonine (with optimal activity at pH 8) in the presence of the manganese divalent cation (Mn
).
PP2C activity was inhibited by sanguinarine (a specific inhibitor) but was unaffected by protein tyrosine phosphatase inhibitors. Western blot analysis indicated that anti-
PP2C antibodies recognized a molecule of 45.2 kDa. Transmission electron microscopy with immunodetection localized
PP2C in the flagellar pocket and flagellum of promastigotes but showed poor staining in amastigotes. Interestingly,
PP2C belongs to the ortholog group OG6_142542, which contains only protozoa of the family Trypanosomatidae. This suggests a specific function of the enzyme in the flagellar pocket of these microorganisms.
The pharmacology of propofol infusions administered for long-term sedation of intensive care unit (ICU) patients has not been fully characterized. The aim of the study was to develop propofol dosing ...guidelines for ICU sedation based on an integrated pharmacokinetic-pharmacodynamic model of propofol infusions in ICU patients.
With Institutional Review Board approval, 30 adult male medical and surgical ICU patients were given target-controlled infusions of propofol for sedation, adjusted to maintain a Ramsay sedation scale score of 2-5. Propofol administration in the first 20 subjects was based on a previously derived pharmacokinetic model for propofol. The last 10 subjects were given propofol based on a pharmacokinetic model derived from the first 20 subjects. Plasma propofol concentrations were measured, together with sedation score. Population pharmacokinetic and pharmacodynamic parameters were estimated by means of nonlinear regression analysis in the first 20 subjects, then prospectively tested in the last 10 subjects. An integrated pharmacokinetic-pharmacodynamic model was used to construct dosing regimens for light and deep sedation with propofol in ICU patients.
The pharmacokinetics of propofol were described by a three-compartment model with lean body mass and fat body mass as covariates. The pharmacodynamics of propofol were described by a sigmoid model, relating the probability of sedation to plasma propofol concentration. The pharmacodynamic model for propofol predicted light and deep levels of sedation with 73% accuracy. Plasma propofol concentrations corresponding to the probability modes for sedation scores of 2, 3, 4, and 5 were 0.25, 0.6, 1.0, and 2.0 microg/ml. Predicted emergence times in a typical subject after 24 h, 72 h, 7 days, and 14 days of light sedation (sedation score = 3 --> 2) with propofol were 13, 34, 198, and 203 min, respectively. Corresponding emergence times from deep sedation (sedation score = 5 --> 2) with propofol were 25, 59, 71, and 74 h.
Emergence time from sedation with propofol in ICU patients varies with the depth of sedation, the duration of sedation, and the patient's body habitus. Maintaining a light level of sedation ensures a rapid emergence from sedation with long-term propofol administration.
La Enfermedad por Coronavirus 2019 (COVID-19) supone un reto sin precedentes para la salud pública. Los médicos deben fortalecer sus habilidades clínicas para combatir esta nueva enfermedad. El ...objetivo de esta revisión fue describir los signos, síntomas y complicaciones de pacientes con COVID-19. Se realizó una búsqueda en la literatura en la base de datos PubMed incluyendo publicaciones entre 1 de diciembre 2019 y 15 de agosto 2020, sin restricciones de lenguaje, utilizando las palabras clave ‘COVID-19’ cruzada con ‘manifestaciones clínicas’, ‘signos y síntomas’ y ‘complicaciones’. Se incluyeron revisiones sistemáticas y meta-análisis, estudios epidemiológicos y series de casos. Se identificaron 1,066 artículos, de los cuales se seleccionaron 71 de acuerdo a los contenidos previamente definidos por los autores. La COVID-19 presenta un curso de leve a moderado y severo-crítico, específicamente en mayores de 65 años con o sin comorbilidades. Los signos y síntomas no son específicos y usualmente se superponen de acuerdo a la edad y a la fase de la enfermedad. Los síntomas más comunes son fiebre, tos y fatiga. Síntomas menos comunes incluyen escalofríos, dolor de garganta, cefalea, mialgias/artralgias, pérdida del gusto y del olfato, diarrea, nausea, vómitos, congestión nasal, palpitaciones, opresión precordial y dolor pleurítico. La sintomatología en niños difiere de la de los adultos y el curso es usualmente benigno y de baja mortalidad. La evaluación clínica de COVID-19 supone un reto hoy en día. Sin embargo, el conocimiento de la historia natural de la enfermedad permite situar los síntomas comunes e inespecíficos en el contexto clínico correcto
Protein phosphatases are enzymes that dephosphorylate tyrosine and serine/threonine amino acid residues. Although their role in cellular processes has been best characterized in higher eukaryotes, ...they have also been identified and studied in different pathogenic microorganisms (e.g., parasites) in the last two decades. Whereas some parasite protein phosphatases carry out functions similar to those of their homologs in yeast and mammalian cells, others have unique structural and/or functional characteristics. Thus, the latter unique phosphatases may be instrumental as targets for drug therapy or as markers for diagnosis. It is important to better understand the involvement of protein phosphatases in parasites in relation to their cell cycle, metabolism, virulence, and evasion of the host immune response. The up-to-date information about parasite phosphatases of medical and veterinarian relevance is herein reviewed.
Making Cities Global A. K. Sandoval-Strausz, Nancy H. Kwak / A. K. Sandoval-Strausz, Nancy H. Kwak
2017, 2017-09-12
eBook
In recent decades, hundreds of millions of people across the world have moved from rural areas to metropolitan regions, some of them crossing national borders on the way. While urbanization and ...globalization are proceeding with an intensity that seems unprecedented, these are only the most recent iterations of long-term transformations—cities have for centuries served as vital points of contact between different peoples, economies, and cultures. Making Cities Global explores the intertwined development of urbanization and globalization using a historical approach that demonstrates the many forms transnationalism has taken, each shaped by the circumstances of a particular time and place. It also emphasizes that globalization has not been persistent or automatic—many people have been as likely to resist or reject outside connections as to establish or embrace them.The essays in the collection revolve around three foundational themes. The first is an emphasis on connections among the United States, East and Southeast Asia, Latin America, and South Asia. Second, contributors ground their studies of globalization in the built environments and everyday interactions of the city, because even world-spanning practices must be understood as people experience them in their neighborhoods, workplaces, stores, and streets. Last is a fundamental concern with the role powerful empires and nation-states play in the emergence of globalizing and urbanizing processes. Making Cities Global argues that combining urban history with a transnational approach leads to a richer understanding of our increasingly interconnected world. In order to achieve prosperity, peace, and sustainability in metropolitan areas in the present and into the future, we must understand their historical origins and development. Contributors: Erica Allen-Kim, Leandro Benmergui, Matt Garcia, Richard Harris, Carola Hein, Nancy Kwak, Carl Nightingale, Amy C. Offner, Margaret O'Mara, Nikhil Rao, A. K. Sandoval-Strausz, Arijit Sen, Thomas J. Sugrue.
Entamoeba histolytica is the causative agent of amoebiasis, and Entamoeba dispar is its noninvasive morphological twin. Entamoeba invadens is a reptilian parasite. In the present study, Western blot, ...phosphatase activity, immunofluorescence, and bioinformatic analyses were used to identify PP2C phosphatases of E. histolytica, E. dispar, and E. invadens. PP2C was identified in trophozoites of all Entamoeba species and cysts of E. invadens. Immunoblotting using a Leishmania mexicana anti-PP2C antibody recognized a 45.2 kDa PP2C in all species. In E. histolytica and E. invadens, a high molecular weight element PP2C at 75 kDa was recognized, mainly in cysts of E. invadens. Immunofluorescence demonstrated the presence of PP2C in membrane and vesicular structures in the cytosol of all species analyzed. The ~75 kDa PP2C of Entamoeba spp. shows the conserved domain characteristic of phosphatase enzymes (according to in silico analysis). Possible PP2C participation in the encystation process was discussed.
PDF
